Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma.
Adolescent
Adult
Aged
Aged, 80 and over
Case-Control Studies
Cohort Studies
Extremities
/ pathology
Female
Follow-Up Studies
Germany
/ epidemiology
Humans
Male
Melanoma
/ diagnosis
Middle Aged
Neoplasm Staging
Prognosis
Skin Neoplasms
/ diagnosis
Survival Analysis
White People
/ statistics & numerical data
Young Adult
Acral lentiginous melanoma
Overall survival
Progosis
Superficial spreading melanoma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
23
03
2021
accepted:
03
04
2021
pubmed:
16
4
2021
medline:
8
2
2022
entrez:
15
4
2021
Statut:
ppublish
Résumé
Acral lentiginous melanoma (ALM), a relatively rare subtype of cutaneous melanoma, has been reported to have a worse prognosis than other melanomas. We aimed to assess clinical findings in Caucasian ALM patients and compare the data with a matched cohort of superficial spreading melanoma (SSM) patients. We studied 63 patients with ALM and 63 randomly stage- and limb-matched patients with SSM (non-ALM). In both cohorts, guideline-adjusted diagnosis, treatment and follow-up were performed. We did not observe differences in prognostic factors (e.g., tumor thickness, ulceration) between the two cohorts. Both in ALM and non-ALM patients positive sentinel lymph node was a significant independent predictor for disease relapse and melanoma-specific death. However, disease relapse and melanoma-specific death rates did not significantly differ between ALM and non-ALM patients. An overall 5-year melanoma-specific survival of 82.5% and 81% was observed in ALM and non-ALM patients, respectively. Our data confirm that patients with ALM have no worse outcome than non-ALM patients when correcting for significant prognostic factors. Hence, the reportedly high rates of fatal ALM cases should not be ascribed to pathobiological differences between ALM and non-ALM but are most likely are a consequence of a delay in diagnosis and thus advanced stage of ALM.
Identifiants
pubmed: 33856527
doi: 10.1007/s00432-021-03630-6
pii: 10.1007/s00432-021-03630-6
pmc: PMC8800911
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-502Informations de copyright
© 2021. The Author(s).
Références
Am J Surg Pathol. 1977 Jun;1(2):131-43
pubmed: 602975
Ann Surg Oncol. 2013 Oct;20(11):3618-25
pubmed: 23838913
J Surg Oncol. 1990 Oct;45(2):91-8
pubmed: 2214797
Br J Dermatol. 2015 Jan;172(1):175-86
pubmed: 24910143
Br J Dermatol. 2020 Apr;182(4):1056-1057
pubmed: 31628856
Ann Surg Oncol. 2020 Sep;27(9):3478-3485
pubmed: 32253677
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2004-2010
pubmed: 31989672
Am J Clin Pathol. 2013 May;139(5):566-73
pubmed: 23596107
Anticancer Res. 2020 Jun;40(6):3411-3415
pubmed: 32487638
J Cutan Med Surg. 2019 Jan/Feb;23(1):38-43
pubmed: 30221995
Br J Dermatol. 2000 Aug;143(2):275-80
pubmed: 10951133
Pathobiology. 2018;85(4):227-231
pubmed: 29860247
Sci Rep. 2016 Aug 22;6:31432
pubmed: 27545198
Ann Diagn Pathol. 2017 Feb;26:64-69
pubmed: 27601330
Pigment Cell Melanoma Res. 2021 Jan;34(1):59-71
pubmed: 32330367
JNCI Cancer Spectr. 2020 Oct 23;4(6):pkaa097
pubmed: 33409460
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):438-442
pubmed: 27518480
Hautarzt. 1994 Aug;45(8):529-31
pubmed: 7960751
Br J Dermatol. 2006 Sep;155(3):561-9
pubmed: 16911282
Mod Pathol. 2021 Mar;34(3):572-583
pubmed: 32759976
J Surg Res. 2020 Jul;251:329-339
pubmed: 32208196
J Am Acad Dermatol. 2018 Oct;79(4):706-713
pubmed: 29673774
J Dtsch Dermatol Ges. 2006 Apr;4(4):344-9
pubmed: 16638065
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Arch Dermatol. 2009 Apr;145(4):427-34
pubmed: 19380664
Br J Dermatol. 2021 Jan;184(1):158-160
pubmed: 32683697